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Abstract 
Importance: Mineralocorticoid Receptor Antagonists (MRAs) are recommended (unless 
contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). 
However, MRAs are still largely underused in routine clinical practice.  
Objective: This study aims to describe the determinants and pattern of use of MRAs in HFrEF.  
Design and Setting:  BIOSTAT-CHF i s  a  European  multicentre, multinational, 
prospective, observational study which enrolled patients who had suboptimal dosing or 
no treatment with ACE-inhibitors/ARBs and/or β-blockers, with the aim of optimizing 
guideline based use of these agents.  
Participants: From the original 2516 subjects, this retrospective post hoc analysis 
included the 1325 patients with an indication for MRA therapy (i.e. LVEF ≤35%, eGFR 
≥30 ml/min/1.73m2, and K+ ≤5.0 mmol/L).  
Results: The mean age was 66.1±12.2 years, and at baseline an MRA was prescribed 741 (56%) 
patients. Patients who were prescribed MRAs at baseline were younger, more often male, had 
higher body mass index, lower sodium, higher proportion of a history of hypertension and 
ACEi/ARBs prescription (all p<0.05). Of the 1049 patients who completed the baseline plus the 
9-month visit, 585 (56%) had an MRA prescribed at baseline and 662 (63%) patients had an 
MRA prescribed at 9 months. Among the 585 patients with MRA at baseline, 91 (16%) had 
discontinued therapy and among the 461 (44%) patients without MRA at baseline 168 (36%) 
had initiated therapy subsequently. MRA discontinuation was more likely in subjects with 
higher LVEF and NYHA class III/IV (p<0.05 for both). MRA prescription both at baseline and 
9 months was not associated with the outcome of death or HF hospitalization (adjusted HR 
[95%CI] =1.02 [0.66-1.58], p=0.93). 
Conclusions and Relevance: In this prospective observational study across Europe, MRAs were 
largely under-prescribed and frequently discontinued. Due to these dynamic changes outcome 
inferences are inconclusive. 
 
Key-words: Mineralocorticoid receptor antagonists; real-life; observational, adherence, 
prescription. 
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Introduction 
Mineralocorticoid receptor antagonists (MRAs) improve morbidity and reduce mortality in 
heart failure with reduced ejection fraction (HFrEF) with severe symptoms (spironolactone)1, 
mild symptoms (eplerenone)2, and in post-myocardial infarction with systolic dysfunction 
and/or heart failure (eplerenone)3. Mortality rates were reduced by 15% to 30% and heart failure 
(HF) readmissions dropped up to 40% in these landmark trials. 
Despite these remarkable improvements in morbidity and mortality and a class IA 
guideline recommendations, MRAs are still largely underused in routine clinical practice4,5. 
Thismay be (at least partly) explained by an undue concern about inducing hyperkalemia or 
worsening renal function6-14 and the need of proper monitoring of potassium and renal function7, 
but also by a lack of education/promotion about these drugs and their indications8-14. 
 “Real-life” data suggest that non-compliance and discontinuation of therapy is 
common, especially with regards to MRAs, with less than 50% of daily doses ingested in some 
series (i.e. a much lower adherence than that reported for angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers [ACEi/ARBs] and β-blockers, for example)15,16. Many 
reports of “real-life” observational data pointed to a lack of association of MRA therapy with 
clinical benefit, in contrast with the findings of multiple randomised clinical trials.  No matter 
how extensive are adjustment in statistical analyses, such observation data are usually fraught 
with residual bias17,18. We hypothesize that one of the major and often overlooked biases is the 
wrong assumption that patients prescribed MRA therapy at baseline keep their medications 
unchanged throughout the course of the observation periods. Hence, the main goals of the 
present analysis are to study: 1) the rates and determinants of MRA prescription; 2) the 
characteristics of the population with and without MRAs prescribed; 3) the changes in MRA 
therapy that occurs after baseline observation and during the 9-month period after the baseline 
observation, and 4) the determinants of these changes. We took advantage of the European 
BIOSTAT-CHF program as a multicentre, multinational, prospective, contemporary, 
observational study which enrolled patients who had suboptimal dosing or no treatment with 
ACE-inhibitors/ARBs and/or β-blockers, with the aim of optimizing guideline based use of 
these agents and examining the predictors of optimization. Patients’ characteristics are 
compared at baseline (visit 1) and 9 months (visit 2) follow up. This retrospective post hoc 
analysis was restricted to patients indicated for MRA therapy. 
 
Methods 
Patient population 
BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres in 11 
European countries to determine profiles of patients with HF that do not respond to 
recommended therapies, despite anticipated up-titration. The design of the study and patients 
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have been described elsewhere19. In brief, patients were aged ≥18 years with symptoms of new-
onset or worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% 
or a BNP and/or NT-proBNP plasma levels >400 pg/ml or >2000pg/ml, respectively. Patients 
needed to be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the 
time of inclusion. Patients should not have been previously treated with evidence based 
therapies (ACEi/ARBs and β-blockers) or were receiving <50% of the target doses of at least 
one of these drugs at the time of inclusion. Initiation or up-titration of ACEi/ARB and/or β-
blocker therapy should have been anticipated by the treating physician. The first three months of 
treatment were considered to be the optimization phase after which a stabilization phase of 6 
months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB 
and/or β-blocker was performed according to the routine clinical practice of the treating 
physicians, who were encouraged to follow the ESC guidelines at the time of treatment20,21. 
There were no inclusion criteria nor optimization strategy specific to MRA therapy, which is 
assumed to be reflective of “usual care”. 
The recruitment period was 24 months, starting from December 2010. The last patient 
was included on December 15, 2012. Median follow-up was 21 months.  
From the original 2516 patients enrolled in the BIOSTAT-CHF program, the 
retrospective analysis only included 1325 patients with a formal indication for the use of an 
MRA (LVEF ≤35%, estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73m2, and 
K+ ≤5.0 mmol/L) – Figure 1.  
Statistical analysis 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation (SD). 
Categorical variables are expressed as frequencies and proportions (%). Population description 
and comparison of patients with MRA vs. without MRA prescribed was performed using 
independent samples t-test for normally distributed continuous variables and chi-square test for 
categorical variables. Normality assumptions were verified by visual binning. No multiple 
imputation was performed.  
To determine predictors of having a MRA prescribed (or not) and discontinued (or not), 
we developed two logistic regression and two multinomial prediction models. Both models used 
clinical and laboratory variables with a p-value <0.2 as entry criteria. The first model was a 
forward conditional model eliminating progressively the variables with weaker association and 
retaining in the final model those variables with a p <0.05. The second model used a stepwise 
backward selection process. Both models provided similar final results.  Logistic regression 
assumptions were checked and multicollinearity excluded. Linear relationship between 
continuous independent variables and the logit transformation of the dependent variable was 
verified by plotting the means vs. the β estimates in quintiles. If a linear relationship was not 
present then the variable was dichotomized at the inflexion point. 
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The primary outcome was a composite of hospitalization for heart failure (HHF) and 
all-cause death. Cox proportional hazard regression models were used to model long-term event 
rate both in univariable and multivariable analysis. Cox models assumptions were verified. An 
interaction term between the variable of interest (MRA) and time was tested within the Cox 
model. In the multivariable models, the covariates for adjustment were chosen from 
demographic (age and gender), clinical (body mass index [BMI], LVEF, European region, 
congestion signs and symptoms, coronary revascularization, hypertension history, diabetes, 
medication, and systolic blood pressure), and laboratory (eGFR determined by the CKD-EPI 
formula22 and hemoglobin). All parameters were previously found to be independently 
associated with the outcome of HF hospitalization or all-cause death in the BIOSTAT cohort. 
These variables were also used to create a propensity score (PS) from a logistic regression 
model. The PS and its Logit were also used for adjustment as covariate providing similar 
results23 (data not shown).   
European region was divided in Southern countries (Greece, Italy, Serbia, Slovenia, and 
France) vs. Northern countries (Netherlands, Sweden, Norway, Germany, Poland, and United 
Kingdom).  
The adjudication of events (heart failure hospitalizations) were done by the treating 
physician.  
All analysis were performed with SAS® software version 9.4 (SAS Institute Inc., Cary, 
N.C., USA). 
 
Results 
Characteristics of the studied population 
At baseline, MRAs were prescribed in 741 (56%) patients. Characteristics of the patients 
according to MRA prescription at baseline and changes in MRA prescription between baseline 
and 9 months are presented in Table 1. Patients with MRA prescription at baseline were 
younger, more often male, had higher BMI, higher potassium levels, lower SBP, lower NT-pro 
BNP, were more often from southern Europe, had worse NYHA class, had more often a cardiac 
device, more coronary interventions, were more often hospitalized for worsening HF in the year 
before the baseline visit, had ACEi/ARBs prescribed more frequently but achieved ≥50% target 
dose of such therapies less frequently, had β-blockers prescribed more frequently but also 
achieved ≥50% target dose of β-blockers less frequently, they also had digoxin prescribed more 
frequently (p<0.05 for all) – Table 1. 
 As compared to patients without any MRA prescription, patients in which an MRA was 
prescribed both at baseline and 9 months were younger, were more often from southern Europe 
(but Southern Europe patients were also the ones who had higher proportion of MRA 
discontinuation at some point between baseline and 9 months), had lower heart rate, lower SBP, 
7 
 
higher serum potassium levels, had more often hypertension history, and a loop diuretic 
prescribed (p<0.05 for all) – Table 1. 
Characterization of patients with and without MRA at baseline 
At baseline, MRA recipients had greater odds of having higher BMI, being from Southern 
Europe, having worse NYHA class, had been hospitalized for worsening HF in the year before 
the baseline visit, have a device implanted, and hypertension history. Patients not receiving 
MRA therapy had higher odds of being older, have higher blood pressure, and hypokalaemia – 
Table 2.  
Factors associated with MRA therapy change up to 9 months during the post discharge 
period  
From the 1325 patients present at baseline, 276 (21%) were lost to follow-up, from which 169 
(61%) died, and 107 (39%) patients did not complete the 9-month visit (data missing). 
Characteristics of these 276 compared with the remaining 1049 patients are depicted in 
Supplementary Table 1.  
Of the 1049 patients who completed both baseline and 9-month visit, an MRA was 
prescribed at baseline in 585 (56%) patients and at 9 months in 662 (63%) patients. Among the 
585 patients with an MRA prescription at baseline, 91 (16%) had discontinued therapy and 
among the 461 (44%) patients without MRA prescription at baseline, 168 (36%) had initiated 
therapy subsequently – Table 3 and Figure 2.  
Factors associated with MRA discontinuation were a higher LVEF and worse NYHA 
class. Having a higher heart rate, SBP ≥140 mmHg and K+ <4 mmol/L at baseline was 
associated with MRA initiation between baseline and 9 months, whereas patients from Southern 
Europe were less likely to initiate an MRA between baseline and 9 months – Table 4. 
Outcome associations 
MRA prescription both at baseline and 9 months was not associated with lower primary 
outcome event rates as compared to not having an MRA prescription (adjusted HR 
[95%CI]=1.02 [0.66-1.58], p=0.93). MRA prescribed only at baseline was associated with 
dismal outcomes in unadjusted models but not after adjustment (unadjusted HR [95%CI]=1.80 
[1.07-3.05], p=0.028 and adjusted HF [95%CI]=1.68 [0.62-3.07], p=0.092).  MRA prescription 
only at 9 months was also not associated with the primary outcome of mortality or heart failure 
hospitalization (adjusted HR [95%CI]=1.50 [0.89-2.53], p=0.13) – Table 5. 
 
Discussion   
Our study based on a symptomatic HFrEF population with suboptimal ACEi/ARB and/or β-
blocker therapy showed that MRAs were largely under-prescribed and frequently changed (i.e. 
discontinued or initiated) in a short follow-up of 9 months. In this population, only ≈56% of 
patients with HFrEF with a formal indication for MRA treatment were actually receiving a 
8 
 
MRA and within 9 months more than 15% of patients receiving an MRA discontinued, while 
another 36% without MRA at baseline initiated. We identified common features and 
determinants for MRA prescription and discontinuation. To the best of our knowledge, this is 
the first report on treatment initiation and cessation in only 9 months’ time. It is, therefore, very 
difficult to categorize patients in observational studies in MRA and non-MRA patients, since 
receiving an MRA therapy is a highly unstable condition and moving target. Consequently, 
reports of observational data, emphasizing lack of association of MRA therapy with clinical 
benefit, are in contrast with the findings of multiple randomised clinical trials. These reports are 
usually fraught with residual biases but are also critically invalidated because all are based on 
the wrong assumption that patients prescribed MRA therapy at baseline keep their medications 
unchanged throughout the course of the observation periods17,18.  
 Previous observational reports confirmed that MRAs are under-prescribed. In the “Get 
With The Guidelines-HF quality improvement registry”4, only about one-third of patients with a 
formal MRA indication (and no compelling contra-indication) had the corresponding 
prescription, that varied widely across United States (US) regions and clinicians. In that 
registry, MRA prescription was also less common among elderly patients, those who have 
worse renal function, and lower blood pressure. In our study patients with higher LVEF and 
worse NYHA class were more likely to have MRAs discontinued between baseline and 9 
months. 
Interestingly, patients with hypertension history more often received MRA therapy, 
whereas patients not receiving MRAs had more often SBP ≥140 mmHg and hypokalemia, 
which is consistent with the anti-hypertensive and potassium-sparing effects of MRA therapy24.  
More frequent use of MRA therapy in patients with highest BMIs suggests that 
clinicians may intuitively perceive that MRA therapy is more effective in overweight patients. 
Actually, experimental and clinical data suggest that this may be the case25. Interestingly, we 
have also recently reported data from the Eplerenone for Heart Failure with Mild Symptoms 
(EMPHASIS-HF) trial suggesting that patients with abdominal obesity derive the largest benefit 
from eplerenone therapy.  
The EURObservational Research Programme: Heart Failure Pilot Survey (ESC-HF Pilot), 
enrolled 5118 patients admitted for acute HF from 136 cardiology centres in 12 European 
countries in 2009-2010. In this survey the rate of MRA therapy at hospital discharge was ~25% 
prior to hospitalization and ~50% after hospitalization26. The use of MRAs in the US is even 
lower than in Europe27,28. Our data suggest that MRA use in the periods between 2009-2010 did 
not improve much up to 2010-2012, with only about half of the patients with compelling 
indication actually receiving the drug. In the 2008 HF guidelines of the European Society of 
Cardiology (ESC) is stated that “aldosterone antagonists should be considered in all patients 
with a LVEF ≤35% and severely symptomatic HF”21, hence most patients included in our study 
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had formal indication for MRAs. It should be noticed that the results of EMPHASIS-HF trial2 
expanding the recommendation of use of MRA therapy to all symptomatic HFrEF patients was 
only integrated in the 2012 ESC guidelines20 and subsequently in the 2016 ESC guidelines29.  
Despite guideline indication, other factors may be responsible for the persistently low 
prescription rate, and these include the excessive concern raised by the publication of 
population-based studies associating the increase of hyperkalemia-associated morbidity and 
mortality30,31 to MRA therapy, after the publication of the RALES (The Effect of Spironolactone 
on Morbidity and Mortality in Patients with Severe Heart Failure: Randomized Aldactone 
Evaluation Study) trial1. As subsequently recognised, patients enrolled in these studies 
commonly received inappropriate dosing of, or had formal contra-indications to MRA therapy, 
and had below trial and guideline recommended serum potassium and renal function 
monitoring32-34. It is also noticeable that there is a poor understanding of the mechanisms of 
action of MRAs beyond their “diuretic with potassium sparing properties” heading35, lack of 
pharmaceutical company–sponsored drug marketing and education for clinicians4, and lack of 
guidance on how to initiate MRAs on a background of ACEi/ARBs and β-blockers up-
titration13,36. The educational gap must be recognized and specifically addressed. Spironolactone 
is a generic drug, orphan from any industry promotional or educational support. Eplerenone is 
hardly supported by its single sponsor because of quick loss of patent short after its market 
launch.  
 In our study, a high rate (more than 15%) of MRA discontinuation during a short period 
of follow-up (≈9months) was observed. However, an even higher rate of MRA initiation (in 
patients without baseline MRA prescription) was observed (36%), possibly reflecting the 
guidance to up-titrate HF therapies in the BIOSTAT program. Patients at the highest end of the 
guideline recommended HFrEF range (<35%) and with worse NYHA class were more likely to 
have MRA treatment discontinued. Moreover, being older was associated with having no MRA 
prescribed at all. Our data do not provide granularity on why patients have stopped the drug, but 
they may suggest that clinicians` perception of patients` status is likely to play a role in these 
decisions and are a potential target for intervention37. Moreover, patient compliance cannot be 
assessed from our data, and compliance with treatments is a major issue38, especially concerning 
MRAs39,40. Notwithstanding, we may observe that potassium levels were higher in the group of 
patients with MRA prescription, which is an indirect sign of compliance.  
 
Clinical and Research Implications 
Our findings, together with other previous observations of under-use and under-dosing of MRA 
therapy should prompt a vigorous call to action. So many reports have consistently emphasised 
the lack of adherence with the highest evidence based strongly recommended life-saving MRA 
therapy in HFrEF, with little proactive action taken, especially in Europe. At least in the US, the 
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Get With The Guidelines initiative (GWTG) is aiming at mitigating the general issue of poor 
adherence to guidelines, with encouraging results5. Actions directed towards clinical education 
and training (not only in the field of Cardiology, but also Internal Medicine, Geriatrics, 
Emergency Medicine, Nephrology, Endocrinology, etc) should be applied in order to improve 
the use of MRA therapy, but also to instruct on how to make the best use of it. Despite several 
reports emphasising the favourable benefit to risk ratio, with persistent clinical benefit despite 
more frequent rise in serum potassium and occasional worsening renal function associated with 
the use of MRA therapy9,41, concern about these adverse events is the primary cause of under-
use and/or under-dosing of MRA therapy42-44. One should be very cautious that the advent of 
new potassium binders7,40,4. Rather than increasing the undue concern about hyperkalaemia as a 
consequence of marketing-based medicine, we should encourage generating appropriate trials 
evidence that these may indeed improve the use of MRA therapy and consequently maximise 
clinical benefit. More frequent and guideline-based potassium and renal function monitoring 
should also be emphasized, given the very low rate of such monitoring associated with the use 
of MRA in daily practice45. Improvement in health-care systems and “HF programmes” such as 
nurse-led HF care, should be widely implemented since they increase adherence to therapy and 
improve outcomes while reducing overall costs46,47,48. From a research perspective, the 
development of point of care home self-monitoring of serum potassium and renal function, 
together with other congestion assessments, backed by electronic algorithms, and other 
prescription-helping tools may improve quality care provision while monitoring performance 
measures. 
 
Limitations 
Several limitations should be noticed in this study. First, this is a secondary analysis of a 
prospective non-randomized observational study, therefore all limitations inherent to such 
analysis are applied herein, including the inability to infer causality (for example, we cannot 
know if patients with worse NYHA class were more likely to have MRA discontinued because 
they were “more sick” or if they were more symptomatic because they did not have MRA 
prescribed). Second, this study was not designed to address MRA prescription with sufficient 
granularity, hence these data do not allow to assess treatment doses or MRA prescription before 
baseline visit. Third, patient selection for the BIOSTAT-CHF study was based on under-
prescription of ACEi and β-blockers, therefore likely also under-prescription of MRAs possibly 
not reflecting “real life” completely, limiting results generalizability and external validity. 
Lastly, association of MRA use with outcome is not possible to be determine due to high rates 
of discontinuation/initiation during follow up. This may be turned in to a strength of this 
manuscript, demonstrating that all “real-life” outcome associations (particularly with MRAs) 
are prone to this type of bias and are therefore potentially misleading.  
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Conclusion 
In this multicenter international European cohort, MRAs were largely underprescribed and 
frequently discontinued. Only slightly more than half of the patients with indication for MRA 
therapy received it and more that 15% of patients discontinued therapy in the few months 
following the baseline visit, while other 36% of patients without MRA prescription at baseline 
initiated it, reflecting the “up-titration” guidance of the BIOSTAT program. We identified 
determinants of prescription and therapy discontinuation and we suggest actionable measures to 
improve prescription and adherence. Given the frequent dynamic changes in therapy, we 
strongly warn against the use of observational data to infer about association between MRA use 
at a certain time point and subsequent outcome. 
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